Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_1

25%

Ph phase_2

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

terminated125%

completed375%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Clinical Trials (4)

Showing 4 of 4 trials

NCT00464555Phase 2

Strategies to Improve Islet Survival

Completed

NCT00437398Phase 1

Islet Transplantation for Type 1 Diabetes Mellitus

Terminated

NCT00175253Phase 2

Alemtuzumab Induction in Islet Transplantation

Completed

NCT00175266Phase 2

Islet Transplantation Using Campath-1H and Infliximab Induction

Completed

All 4 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 4